Not all of the dangerous, controversial drugs are banned in baseball

64 Comments

We get up in arms about testosterone and HGH — substances our bodies naturally produce and which have few serious side effects or long-lasting consequences — because they’re on a banned list. Meanwhile there’s a drug that a lot of athletes take under the direction and supervision of their teams which can kill people and is banned in several countries: the anti-inflammatory Toradol.

Gordon Edes of ESPN Boston has a story about its use in baseball. The hook: an interview with Jonathan Papelbon who took it routinely when he was with the Red Sox but who was told by the Phillies that he can no longer take it as they do not allow it.  Edes looks into the controversial drug, notes its serious side effects, which can include internal bleeding (Clay Buchholz believes it’s what led to him contracting esophagitis which landed him in the ICU) and notes that it’s banned in several countries, for athletes and normal folks alike.

Papelbon’s description of its use in Major League Baseball is pretty familiar-sounding: it’s taken before the game to help guys “get through a 162 game season.” It’s, by definition, a performance enhancing drug. It’s letting guys do things they otherwise couldn’t do. Allowing their bodies to recover faster which allows them to train harder and compete at a more intense level than they otherwise could. Except it’s not on a banned list so no one cares despite the fact that it has the potential to kill you.

There is a tremendous disconnect between the drugs people think are awful in sports and the drugs that truly have the potential to be harmful. This is maybe the best example. Might be nice if we thought about our priorities about these things once in a while.

Report: Brewers sign Mike Moustakas to one-year, $10 million contract

Harry How/Getty Images
1 Comment

Ken Rosenthal of The Athletic reports that the Brewers have signed free agent third baseman Mike Moustakas to a one-year contract, pending a physical. The deal is worth $10 million, per Bob Nightengale of USA TODAY Sports.

Moustakas, 30, was traded to the Brewers from the Royals ahead of the non-waiver trade deadline last season. Between both clubs, he hit .251/.315/.459 with 28 home runs and 95 RBI in 635 plate appearances.

Last March, Moustakas signed a one-year, $6.5 million deal with the Royals that included a $15 million mutual option for the 2019 season. The Brewers declined that option at the end of October and ended up waiting him out to save $5 million.

Travis Shaw had been in line to be the Brewers’ starting third baseman, but with Moustakas back in the mix, Shaw likely moves over to second base.